TCTR20180720002
Active, not recruiting
Phase 2
Magnesium sulfate as an adjuvant therapy in neonatal hypoxia
Tanta university hospital0 sites60 target enrollmentJuly 20, 2018
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- neonatal hypoxia
- Sponsor
- Tanta university hospital
- Enrollment
- 60
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •hypoxic ischemic encephalopathy, S100\-b, magnesium sulfate, neonates
Exclusion Criteria
- •congenital anomalies, intra uterine growth retardation (I.U.G.R), neonatal sepsis, infant of diabetic mother (I.D.M).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Role of Magnesium suplhate to mother in protecting brain of preterm babiesHealth Condition 1: null- Preterm infantsCTRI/2018/06/014386PGIMS
Recruiting
Not Applicable
Antenatal magnesium sulphate for protection of the preterm brain in women at risk preterm delivery at 28-36 weeks gestatioNervous System DiseasesPACTR202404671084461Dr Linda James Audu90
Not yet recruiting
Phase 3
Magnesium Sulphate as Adjuvant in Acute Organophosphorus PoisoningCTRI/2024/02/063307JLN Medical College and Hospital
Active, not recruiting
Phase 1
Does magnesium sulphate prevent cerebral palsy in very preterm born infants?EUCTR2011-000735-80-DKene Drasbek Huusom560
Recruiting
Not Applicable
Magnesium sulphate ( magsalf) for fetal neuroprotection.Health Condition 1: O368- Maternal care for other specifiedfetal problemsCTRI/2019/05/019293King Georges Medical University